• 1
    Ho DD. Therapy of HIV infections: problems and prospects. Bull NY Acad Med. 1996;73:37 45.
  • 2
    Mehta S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665 70.
  • 3
    Samet JH, Libman H, Steger KA, et al. Compliance with zidovudine therapy in patients infected with human immunodeficiency virus, type-1: a cross-sections study in a municipal hospital clinic. Am J Med. 1992;92:495 502.
  • 4
    Aversa SL & Kimberlin C. Psychosocial aspects of antiretroviral medication use among HIV patients. Patient Educ Couns. 1996; 29:207 19.
  • 5
    Morse EV, Simon PM, Coburn M, Hyslop N, Greenspan D, Balson PM. Determinants of subject compliance within an experimental anti-HIV drug protocol. Soc Sci Med. 1991;32:1161 7.
  • 6
    Hecht FM. Adherence to HIV Treatment. Presented at the meeting of Clinical Care of the AIDS Patients, San Francisco, Calif, December 1997.
  • 7
    Perry S, Ryan J, Ashman T, Jacobsberg L. Refusal of zidovudine by HIV-positive patients. AIDS. 1992;6:514 5.
  • 8
    Rabkin JG & Chesney M. Treatment adherence to HIV medications: the Achilles heel of the new therapeutics. In: OstrowD, KalichmanS, eds. Behavioral and Mental Health Impacts of New HIV Therapies. New York, NY: Plenum Press. 1999.
  • 9
    Ickovics JR & Meisler AW. Adherence in AIDS clinical trials: a framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385 91.
  • 10
    Stall R, Hoff C, Coates TJ, et al. Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J AIDS Hum Retrovir. 1996; 11:151 60.
  • 11
    Singh N, Squier C, Sivek M, Wagener M, Nguyen M, Yu VL. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: prospective assessment with implications for enhancing compliance. AIDS Care. 1996;8:261 9.
  • 12
    Broers B, Morabia A, Hirschel B. A cohort study of drug users’ compliance with zidovudine treatment. Arch Intern Med. 1994;154: 1121 7.
  • 13
    O’Connor PG & Samet JH. The substance-using human immunodeficiency virus patient: approaches to outpatient management. Am J Med. 1996;101:435 44.
  • 14
    Parker RM, Baker DW, Williams MV, Nurss JR. The test of functional health literacy in adults: a new instrument for measuring patients’ literacy skills. J Gen Intern Med. 1995;10:537 41.
  • 15
    Williams MV, Parker RM, Baker DW, et al. Inadequate functional health literacy among patients at two public hospitals. JAMA. 1995;274:1677 82.
  • 16
    Derogatis LR & Melisaratos N. The Brief Symptom Inventory: an introductory report. Psychol Med. 1983;13:595 605.
  • 17
    Cella D. The Functional Assessment of Cancer Therapy Scales and the Functional Assessment of HIV Infection Scale, Version 3. Chicago, Ill: Rush–Presbyterian–St. Lukes Medical Center. 1994.
  • 18
    Hecht FM, Colfax G, Swanson M, Cesney M. Adherence and effectiveness of protease inhibitors in clinical practice. Presented at the 5th Annual Retroviral Conference, Chicago, Ill, 1998.
  • 19
    Hopewell PC. Tuberculosis in persons with human immunodeficiency virus infection. In: SandeMA, VolberdingPA, eds. The Medical Management of AIDS. 5th ed. Philadelphia, Pa: Saunders; 1997:311 26.
  • 20
    Sikkema K & Kelly J. Behavioral medicine interventions can improve quality of life and health of persons with HIV disease. Ann Behav Med. 1996;18:40 8.
  • 21
    Kalichman SC. Understanding AIDS: Advances in Research and Treatment. 2nd ed. Washington, DC: American Psychological Association; 1998.
  • 22
    Besch CL. Compliance in clinical trials. AIDS. 1995;9:1 10.
  • 23
    Dixon L, Weiden P, Torres M, Lehman A. Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiatry. 1997;154:1302 4.